Elucidating the specific pharmacological mechanism of action (MOA) of naturally happening compounds may be difficult. Although Tarselli et al. (60) designed the initial de novo artificial pathway to conolidine and showcased that this naturally developing compound correctly suppresses responses to the two chemically induced and inflammation-derived … Read More


Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements analyze discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3… Read More